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Abstract
Neuropathological and genetic findings suggest that the presynaptic protein α-synuclein (aSyn) is involved in the
pathogenesis of synucleinopathy disorders, including Parkinson’s disease (PD), dementia with Lewy bodies (DLB)
and multiple system atrophy. Evidence suggests that the self-assembly of aSyn conformers bound to phospholipid
membranes in an aggregation-prone state plays a key role in aSyn neurotoxicity. Accordingly, we hypothesized that
protein binding partners of lipid-associated aSyn could inhibit the formation of toxic aSyn oligomers at membrane
surfaces. To address this hypothesis, we characterized the protein endosulfine-alpha (ENSA), previously shown to
interact selectively with membrane-bound aSyn, in terms of its effects on the membrane-induced aggregation and
neurotoxicity of two familial aSyn mutants, A30P and G51D. We found that wild-type ENSA, but not the non-aSyn-
binding S109E variant, interfered with membrane-induced aSyn self-assembly, aSyn-mediated vesicle disruption and
aSyn neurotoxicity. Immunoblotting analyses revealed that ENSA was down-regulated in the brains of
synucleinopathy patients versus non-diseased individuals. Collectively, these results suggest that ENSA can alleviate
neurotoxic effects of membrane-bound aSyn via an apparent chaperone-like activity at the membrane surface, and
a decrease in ENSA expression may contribute to aSyn neuropathology in synucleinopathy disorders. More generally,
our findings suggest that promoting interactions between lipid-bound, amyloidogenic proteins and their binding
partners is a viable strategy to alleviate cytotoxicity in a range of protein misfolding disorders.
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Introduction
The presence of cytoplasmic inclusions containing ag-
gregated forms of the presynaptic protein α-synuclein
(aSyn) is characteristic of a panel of neurodegenerative
diseases commonly referred to as synucleinopathies, in-
cluding Parkinson’s disease (PD), dementia with Lewy
bodies (DLB) and multiple system atrophy [49]. PD is
further characterized by a loss of dopaminergic neurons
in the substantia nigra region of the brain. Autosomal
dominant mutations in the SNCA gene encoding aSyn,
including substitutions (A30P, E46K, H50Q, G51D,
A53E, and A53T) and gene multiplications, have been
linked to familial forms of PD [42, 43, 48]. Some aSyn
substitution mutants have an increased propensity to ag-
gregate into soluble oligomers or insoluble fibrils [12],
and gene multiplications are predicted to promote aSyn
aggregation via mass action. Accordingly, it is hypothesized
that preventing the initiation of aSyn aggregation could be
neuroprotective in PD and other synucleinopathies.
aSyn is most commonly expressed as a 14 kDa (140-
residue) protein. Evidence suggests that the protein
exists as a natively unfolded monomer in solution [56]
and as a compact disordered monomer in mammalian
cells [51], although other findings suggest that it can
also adopt multimeric structures in the cytoplasm [5].
The protein consists of 3 regions: an N-terminal re-
gion containing a series of lysine-rich repeats, a cen-
tral hydrophobic region, and a C-terminal region
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enriched with proline residues and acidic residues.
aSyn interacts with anionic phospholipid vesicles by
forming an amphipathic α-helix (most likely an α11/3
helix) with various lengths, ranging from a short helix
spanning residues ~1–25 to a long helix spanning resi-
dues ~1–97 and including the central hydrophobic re-
gion [4, 6, 9, 25], and this interaction is thought to be
necessary for the protein’s function in regulating syn-
aptic vesicle trafficking [13, 16, 53].
aSyn has been shown to undergo accelerated aggrega-
tion at membrane surfaces when incubated with synthetic
or natural phospholipid vesicles [20, 27, 36] or supported
lipid bilayers [22, 41], presumably because the two dimen-
sional surface of the membrane increases the probability
of molecular interactions needed for oligomerization [1].
Membrane-induced aSyn aggregation is likely driven by a
disruption of contacts between the central hydrophobic
domain and the membrane, resulting in the exposure of
hydrophobic residues that can then engage in interactions
involved in aSyn self-assembly [6, 58]. Evidence suggests
that aSyn aggregation on the membrane plays a key role
in neurotoxicity [58], potentially by triggering membrane
thinning, a process that could result in increased ion
permeability [11, 37, 44].
Based on evidence that membrane-induced aSyn ag-
gregation plays a key role in aSyn-mediated neurodegen-
eration, we hypothesize that proteins that interact with
membrane-bound aSyn can interfere with the formation
of neurotoxic aSyn oligomers at the membrane surface.
This inhibitory effect could involve a shift in the equilib-
rium of membrane-bound aSyn species in favor of a less
exposed state or a disruption of interactions between
neighboring exposed aSyn conformers on the bilayer. To
address this hypothesis, we examined the effects of
the protein endosulfine-alpha (ENSA) on membrane-
induced aSyn aggregation and aSyn neurotoxicity. ENSA,
a 13 kDa protein that is a member of the cAMP-regulated
phosphoprotein family, has a defined role in cell cycle
regulation in various tissues but is also expressed in post-
mitotic neurons in the CNS [17]. Although the role of
ENSA in the CNS is poorly understood, the protein
has been found to be significantly down-regulated in
Alzheimer’s disease (AD) and in Down syndrome [30, 31].
Wild-type (WT) ENSA, but not a variant with the
S109E phosphomimetic substitution, was shown to bind
specifically to membrane-associated aSyn, but not aSyn
in the absence of phospholipids [7, 57]. Here, we charac-
terized WT ENSA and S109E in terms of their impact on
membrane-induced aggregation, vesicle permeabilization,
and dopaminergic cell death elicited by the familial
aSyn mutants, A30P and G51D. Our results provide
strong support for the idea that aSyn aggregation at
membrane surfaces plays a key role in aSyn neurotox-
icity, and they suggest that stabilization of membrane-
bound aSyn could be a therapeutic strategy for PD
and other synucleinopathy disorders.
Materials and methods
Materials
Unless otherwise stated, all chemicals were purchased from
Sigma-Aldrich (St. Louis, MO). Isopropyl β-D-1-thio-
galactopyranoside (IPTG), ampicillin, and phenylmethyl-
sulfonyl fluoride (PMSF) were purchased from Gold
Biotechnology (St. Louis, MO). L-α-phosphatidylcholine
(egg PC), L-α-phosphatidylglycerol (egg PG), and phospho-
lipid extrusion membranes were purchased from Avanti
Polar Lipids (Alabaster, AL). Dulbecco’s minimal essential
media (DMEM), penicillin-streptomycin, the ViraPower
Adenoviral Expression System, and LR clonase II were ob-
tained from Invitrogen (Carlsbad, CA). Fetal bovine serum
(FBS) was obtained from Corning Life Sciences (Corning,
NY). Iodixanol and ECF substrate were obtained from GE
Life Sciences (Pittsburgh, PA). 100 kDa spin filters were
purchased from Millipore (Billerica, MA). Bicinchoninic
acid (BCA) assay reagents and Coomassie Brilliant Blue
were purchased from Thermo Scientific (Rockford, IL).
Antibodies
The following antibodies were used in these studies:
mouse anti-aSyn (#610787, BD Biosciences, San Jose, CA);
rabbit anti-ENSA (#D5Z1U), rabbit anti-β3-tubulin
(#D65A4), and AP-linked anti-mouse and anti-rabbit IgG
(Cell Signaling Technology, Danvers, MA); chicken anti-
MAP2 (#CPCA-MAP2, EnCor Biotechnology, Gainesville,
FL); rabbit anti-TH (#AB152, Millipore, Billerica, MA);
mouse anti-β-actin (#A5316 or #A5441, Sigma-Aldrich);
and anti-rabbit IgG-Alexa Fluor 488 and anti-chicken
IgG-Alexa Fluor 594 (Invitrogen, Carlsbad, CA).
Protein purification
Recombinant aSyn was purified from BL21 (DE3) cells
transformed with pT7-7 constructs encoding A30P or
G51D as described [58]. A cDNA encoding S109E was
generated via overlap-extension PCR using a pET21-
ENSA construct as the DNA template and cloned as an
NdeI-BamHI fragment into the pT7-7 expression vector.
Protein expression was induced by adding IPTG (final
concentration, 1 mM) to an E. coli culture pre-grown to
an OD600 of 0.6, and the culture was incubated at 37 °C
for 3 h. The cells were harvested by centrifugation, sus-
pended in a buffer consisting of 10 mM Tris HCl,
pH 7.4, 1 mM PMSF, and 1 mM EDTA, and lysed with
a French pressure cell (psi 1000). After lysis, 0.1% (w/v)
streptomycin sulfate was added to the lysate, which was
then cleared by centrifugation. ENSA was partially
purified from the resulting supernatant by ammonium
sulfate precipitation (30% saturation). The pellet was
re-suspended in 10 mM Tris HCl, pH 7.4, and loaded
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on a DEAE-Sepharose anion exchange column. The
column flow-through was analyzed by SDS-PAGE, and
fractions containing ENSA were loaded onto a Sephacryl
S-100 column. Fractions enriched with ENSA to a purity
of >98%, as determined by SDS-PAGE with Coomassie
Blue staining, were pooled, concentrated, aliquoted, and
stored at −80 °C until use.
Lipid vesicle preparation
Small unilamellar vesicles (SUVs) were prepared as de-
scribed [58]. Egg PG and egg PC suspended in chloro-
form were mixed at an equimolar ratio in a round
bottom flask. The chloroform was evaporated under a
nitrogen stream and further dried under vacuum for 1 h.
Dried lipids were suspended in PBS (10 mM phosphate
buffer, 2.7 mM KCl, and 137 mM NaCl, pH 7.4), and
50 nm SUVs were prepared by extruding the suspension
through a Whatman membrane. The size of the vesicles
was confirmed by dynamic light scattering. Lipid vesicles
were stored at 4 °C prior to use.
Lipid flotation assay
Lipid flotation analyses were carried out as described
[58]. aSyn was dialyzed overnight into PBS with 0.02%
(w/v) NaN3, and the solution was filtered by successive
centrifugation steps through a 0.22 μm spin filter and a
100 kDa centrifugal filter to isolate monomeric protein.
aSyn (40 μM) was incubated with PG:PC SUVs (protein-
to-lipid ratio, 1:20 mol/mol) in the absence or presence
of ENSA (10–40 μM) at 37 °C for 72 h in a total vol-
ume of 60 μL. After incubation, the sample was mixed
with 4 mL of 30% (v/v) iodixanol solution and overlaid
with 7.0 mL of 25% (v/v) iodixanol and 350 μL of 5%
(v/v) iodixanol in a polyalomar tube (Beckman, Miami,
FL). All of the above iodixanol solutions were prepared
in lipid flotation buffer (10 mM HEPES, pH 7.4,
150 mM NaCl). The samples were spun at 200,000 × g
in a Beckman SW 41 Ti rotor for 4 h. The membrane
fraction was carefully collected from the 5% iodixanol
fraction at the top of the gradient, concentrated using
a 10 kDa spin filter, and stored at −20 °C prior to
Western blot analysis.
Membrane-bound proteins isolated by lipid flotation
were analyzed by Western blotting as described [58].
Protein samples were combined with Laemmli buffer
(final concentration, 60 mM Tris HCl, pH 6.8, 2% (w/v)
SDS, 10% (v/v) glycerol, 5% (v/v) β-mercaptoethanol,
0.01% (w/v) bromophenol blue) and boiled for 2 min.
Denatured proteins were separated via SDS-PAGE on a 4–
20% (w/v) polyacrylamide gradient gel (BioRad, Hercules,
CA) and transferred to a polyvinylidene difluoride (PVDF)
membrane (pore size, 0.4 μm). After blocking in 10% (w/v)
non-fat milk, the membrane was washed with PBS + 0.5%
Tween 20 (w/v) (PBS-T) and probed for aSyn with the
Syn-1 primary antibody, diluted 1/2000 in PBS-T with 1%
(w/v) BSA. After washing in PBS-T, the membrane was
probed with a secondary anti-mouse antibody conjugated
to alkaline phosphatase (diluted 1/3000). To visualize the
bands, the membrane was exposed to ECF substrate for
30 s, and images were acquired using a Typhoon imaging
system (GE Life Sciences, Pittsburgh, PA). Band densities
were quantified using ImageJ software (NIH, Bethesda,
MD). Oligomer band intensities were determined by carry-
ing out a densitometric analysis of the region of the gel
spanning predicted molecular weights of 30 kDa through
250 kDa. We verified using ImageJ software that the band
intensities were below the saturation range. In general,
we found that the rate of aSyn aggregation increased in
the presence of SUVs that had been stored for ~2-4
weeks at 4 °C [58].
Membrane disruption assay
Calcein-loaded egg PG:PC SUVs were prepared as de-
scribed [3] with some modifications. A solution of
calcein (170 mM) was prepared in H2O using NaOH
to adjust the pH to 7.4. The final osmolality was
280 mOsm/kg. The calcein solution was used to re-
suspend dried egg PG:PC lipids, and the suspension
was extruded through a Whatman membrane to gen-
erate 50 nm SUVs. Calcein-containing vesicles were
isolated from free calcein via gel filtration through a
Sephadex G-50 column pre-equilibrated with PBS,
pH 7.4, 0.02% (w/v) NaN3 (280 mOsm/kg). Fractions
containing isolated vesicles were pooled and stored at
4 °C until use. Calcein-loaded vesicles were found to
be very stable, with no spontaneous dye leakage ob-
served over several weeks.
For membrane disruption experiments, monomeric
aSyn was isolated as described above (see ‘Lipid
Flotation Assay’) and dialyzed into PBS with 0.02% (w/v)
NaN3. aSyn (40 μM) was incubated with calcein-loaded
PG:PC SUVs (protein-to-lipid ratio, 1:20 mol/mol) in the
absence or presence of ENSA (10–40 μM) at 37 °C in a
total volume of 50 μL. At each time point, 3 μL of the
reaction mixture was diluted into 180 μL of PBS, and
the diluted samples were analyzed with a Fluoromax-3
spectrofluorometer (Horiba Scientific, Edison, New Jersey)
(excitation wavelength, 485 nm; emission wavelengths,
505–530 nm; slit width, 1 nm). To determine the max-
imum dye release, vesicles were lysed by adding 5 μL of
1% (v/v) Triton X-100. The % leakage at time t was deter-
mined using the following equation:
% leakage ¼ It−I0
Imax−I0
 100%
where It is the fluorescence emission intensity at time t,
I0 is the intensity at time 0, and Imax is the maximal
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intensity determined after detergent lysis of the vesicles
(intensity values were determined at 515 nm).
aSyn fibrillization
aSyn fibrillization rates were assessed using a thioflavin
T fluorescence assay as described [59], with some modi-
fications. Monomeric aSyn prepared as outlined above
(see ‘Lipid Flotation Assay’) was diluted to a final con-
centration of 40 μM in a solution of PBS, pH 7.4, 0.02%
(w/v) NaN3, and 20 μM thioflavin T, and the diluted
protein solution was aliquoted in triplicate in a 96-well
microtiter plate (200 μL per well). A Teflon ball was
added to each well to enhance mixing. The plate was
incubated at 37 °C with constant shaking in a Genios
plate reader (Tecan, Uppsala, Sweden). The formation
of amyloid-like fibrils was monitored by measuring
thioflavin T fluorescence (excitation wavelength, 440 nm;
emission wavelength, 480 nm), with one reading taken
every 15 min.
Preparation of adenoviral constructs
Adenoviruses encoding aSyn and ENSA variants were
produced using the ViraPower Adenoviral Expression
System. Methods used to generate aSyn-encoding
adenoviral DNAs were described previously [58]. A
cDNA encoding ENSA was cloned as a KpnI-XhoI frag-
ment into the pENTR1A entry plasmid, and the insert
from the pENTR1A construct was transferred into the
pAd/CMV/V5 adenoviral expression vector via recom-
bination using Gateway LR Clonase. The sequence of
the DNA insert in the resulting adenoviral construct was
verified using an Applied Biosystems (ABI3700) DNA
sequencer (Purdue Genomics Core Facility).
A low-titer preparation of each adenovirus was produced
by lipid-mediated transfection of the HEK 293A packaging
cell line with adenoviral DNA. The low-titer preparation
was then applied to a new batch of HEK 293A cells to gen-
erate an amplified virus preparation. Adenovirus packaged
with the plasmid pAd/V5-DEST/LacZ (Invitrogen), encod-
ing the control protein β-galactosidase (β-gal) fused to the
V5 epitope, was also prepared to control for non-specific ef-
fects of viral transduction.
Preparation and treatment of primary mesencephalic
cultures
Primary midbrain cultures were prepared via dissection
of day 17 embryos obtained from pregnant Sprague-
Dawley rats (Envigo (Harlan), Indianapolis, IN) using
methods approved by the Purdue Animal Care and Use
Committee, as described [39, 58]. The mesencephalic
region containing the substantia nigra and ventral teg-
mental area was isolated stereoscopically, and the tissue
was treated with trypsin (final concentration, 26 μg/mL
in 0.9% [w/v] NaCl). Dissociated cells were plated on 96-
well plates (pretreated with poly-L-lysine, 5 μg/mL) at a
density of 82,000 cells per well in media consisting of
DMEM, 10% (v/v) FBS, 10% (v/v) horse serum, penicillin
(10 U/mL), and streptomycin (10 μg/mL). Five days after
plating, the cells were treated for 48 h with cytosine
arabinofuranoside (20 μM) to inhibit the growth of glial
cells. At this stage (7 days in vitro), the cultures were
transduced for 72 h with adenoviruses encoding aSyn
variants at a multiplicity of infection (MOI) of 10, with
or without adenovirus encoding ENSA at an MOI of 5.
Adenovirus encoding β-gal was used as a control for
viral transduction. The cultures were then incubated in
fresh media for an additional 24 h, and immunocyto-
chemistry was performed as described [58]. The cells
were fixed in 4% (w/v) paraformaldehyde in PBS
(pH 7.4) and subsequently permeabilized for 1 h with
PBS, pH 7.4, 0.3% (v/v) Triton X-100, 1% (w/v) BSA,
and 10% (v/v) FBS. After washing with PBS, the cells
were treated for 48 h at 4 °C with chicken anti-MAP2
(1:2000) and rabbit anti-TH (1:500) primary antibodies.
The cells were then washed with PBS, treated with Alex-
aFluor 594-conjugated goat anti-chicken and AlexaFluor
488-conjugated goat anti-rabbit secondary antibodies
(both at 1:1000) for 1 h at 22 °C, and washed a final time
with PBS before imaging.
Measurement of neuronal viability
Relative dopaminergic cell viability was assessed by count-
ing MAP2- and TH-immunoreactive primary neurons in
a blinded manner [58]. The neurons were imaged using
an automated Cytation 3 Cell Imaging Multi-Mode
Reader (BioTek, Winooski, VT) equipped with a 4× ob-
jective. A total of 9 images were taken to provide repre-
sentation of the whole well, and at least 900 MAP2+
neurons were counted per experiment for each treatment.
Each experiment was repeated using cultures prepared
from at least 3 different pregnant rats. The data are
expressed as a percentage of MAP2+ neurons that were
also TH+ to correct for variations in cell plating density.
Neurite length measurements
Neurite length measurements were carried out on the
same images generated by the Cytation 3 cell imager for
neuron viability analysis. Lengths of MAP2+ processes
extending from TH+/MAP2+ neurons with an intact cell
body (>40 neurons and >70 neurites per experiment
for each treatment) were assessed in a blinded man-
ner using the Nikon NIS Elements analysis software
(Nikon Instruments, Melville, NY) [58].
Analysis of brain tissue homogenates
Research involving analyses of coded human brain sam-
ples was granted an exemption from requiring ethics ap-
proval by the Purdue University and Indiana University
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Institutional Review Boards. The French brain samples were
obtained from brains collected in a Brain Donation Program
of the Brain Bank “GIE NeuroCEB” run by a consortium of
Patients Associations: ARSEP (association for research on
multiple sclerosis), CSC (cerebellar ataxias), France Alzheimer
and France Parkinson. The consents were signed by the pa-
tients themselves or their next of kin in their name, in accord-
ance with the French Bioethical Laws. The Brain Bank GIE
NeuroCEB (Bioresource Research Impact Factor number BB-
0033-00011) has been declared at theMinistry of Higher Edu-
cation and Research and has received approval to distribute
samples (agreement AC-2013-1887). Samples of human cor-
tex and substantia nigrawere resuspended at a concentration
of 0.1 mg/mL in RIPA buffer (50 mM Tris HCl, pH 7.4,
150mMNaCl, 0.1% (w/v) SDS, 0.5% (w/v) sodium deoxycho-
late, 1% (v/v) Triton X 100) supplemented with protease in-
hibitor cocktail (Sigma P8340) and PMSF (1 mM). The tissue
was homogenized by cup sonication at 4 °C using a Digital
Sonifier (Branson, Danbury, CT). The homogenate was
cleared by centrifugation at 13,000 × g, and the supernatant
was fractionated via SDS-PAGE (20 μg of protein loaded in
each lane of a 16% (w/v) polyacrylamide gel) and analyzed via
Western blotting (primary antibody: rabbit anti-ENSA,
1:1,000 or 1:2,000; rabbit anti-β3-tubulin, 1:5,000; or mouse
anti-β-actin, 1:10,000 (Sigma-Aldrich #A5316) or 1:1,000
(Sigma-Aldrich #A5441); secondary antibody: AP-conjugated
anti-rabbit IgG or anti-mouse IgG, 1:3000). ENSAband inten-
sities were determined via densitometric analysis using the
ImageJ software and normalized to their respective β-3-
tubulin band intensities. In turn, these ratios were normal-
ized to the control ENSA/β-3-tubulin ratio.
Statistical analysis
Densitometry data from Western blots, calcein dye release
data, and primary neuron viability data were analyzed via two-
tailed t-test (when comparing 2 groups) or ANOVA followed
by Tukey’s multiple comparisons post hoc test (when compar-
ing >2 groups) using GraphPad Prism 6.0 (La Jolla, CA). In
analyzing percentage dye release data and percentage cell via-
bility data by ANOVA, square root transformations were car-
ried out to conform to ANOVA assumptions. Neurite length
data were analyzed using an approach that accounts for (i) the
possibility of multiple neurites arising from a single cell, and
(ii) comparison across experiments conducted on different
days [58]. Neurite lengths for multiple treatment groups were
compared using a general linear model implemented in the
GLM procedure of SAS Version 9.3 followed by the Tukey’s
multiple comparisons post hoc test (Cary, NC).
Results
Effect of ENSA on membrane-induced self-assembly of
A30P and G51D
The goal of this study was to test the hypothesis that
promoting interactions between membrane-associated
aSyn and a binding partner at the membrane surface could
interferewith lipid-induced aSyn aggregation and aSyn neuro-
toxicity. To address this hypothesis, we examined the impact
of the aSyn-binding protein ENSA on themembrane-induced
self-assembly and associated membrane permeabilization ac-
tivity of toxic aSyn variants. We then sought to determine
whether effects of ENSA on membrane-induced aSyn aggre-
gation and aSyn-mediated vesicle disruption in a cell-free sys-
tem translated into effects on aSyn neurotoxicity in a primary
midbrain culture model of PD. Our rationale for characteriz-
ing the effects of ENSA was that this protein has been shown
to interact with membrane-bound aSyn, whereas it does not
bind to aSyn in the absence of phospholipids [57]. Our ap-
proach of examining the A30P and G51D familial aSyn mu-
tants was based on our previous finding that both variants
bind SUVs with a relatively exposed conformation and have a
high propensity to undergomembrane-induced self-assembly
and elicit neurotoxicity [58]. In contrast,WTaSynwas not ex-
amined here because it has a lower propensity to form aggre-
gates at membrane surfaces and is only weakly neurotoxic in
our primarymidbrain culturemodel.
To determine the effect of ENSA on membrane-induced
aSyn aggregation, recombinant monomeric A30P or G51D
aSyn (40 μM) was incubated with SUVs (800 μM) containing
egg PG and egg PC (1:1 mol/mol), in the absence or pres-
ence of WT ENSA (10, 20, or 40 μM), at 37 °C for 72 h. We
chose to examine PG:PC SUVs because previously we found
that this heterogeneous lipid mixture was compatible with
the formation of highly stable 50 nm vesicles [58], and SUVs
derived from this mixture contain anionic lipids that play a
key role in aSyn-membrane interactions [13, 16, 28]. In
addition, neuronal membranes (e.g. synaptic vesicle mem-
branes) consist of a mixture of zwitterionic and anionic
phospholipids [45, 50]. After the incubation, the membrane
fraction was isolated by lipid flotation and analyzed by West-
ern blotting. The lanes containing A30P and G51D incu-
bated in the absence of ENSA displayed pronounced
immunoreactive bands at 37, 55 and, 80 kDa and a smear-
ing of immunoreactivity at higher molecular weights,
corresponding to SDS-resistant aggregates (Fig. 1a, c, e, g
). Co-incubation of A30P or G51D with ENSA resulted in
a decrease in the intensity of the higher molecular
weight bands, and densitometric analysis revealed that
the magnitude of this decrease was greater for aSyn sam-
ples incubated with higher amounts of ENSA (a significant
decrease in intensity of ~40 and ~50% was observed for
the 20 and 40 μM ENSA treatment groups, respectively)
(Fig. 1b, f ). In contrast to WT ENSA, the S109E vari-
ant previously shown to have a reduced affinity for
membrane-bound aSyn [7] had no impact on the for-
mation of high molecular weight species by A30P
(Fig. 1c, d) or G51D (Fig. 1g, h) in the presence of
SUVs, even when added to the aSyn-lipid mixture at
an equimolar level relative to the aSyn protein.
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We observed that the intensity of the monomer band in the
vesicle fraction was greater for A30P or G51D incubated in the
absence versus the presence ofWT ENSA, or for mutant aSyn
incubated in the presence of S109E versus WT ENSA. Similar
amounts of membrane-bound aSyn were detected in A30P- or
G51D-lipid mixtures incubated with or withoutWT ENSA for
3 h at 37 °C, conditions permissive for aSyn-lipid binding
but not membrane-induced aggregation (Additional file 1:
Figure S1). Accordingly, we inferred that the increased
monomer immunoreactivity in the membrane fractions of
aSyn-lipid mixtures incubated in the absence of ENSA or
in the presence of S109E was not due to a greater degree
of direct aSyn-vesicle binding, but instead it was a result of
the recruitment of unbound monomer from the bulk solu-
tion to growing membrane-bound aggregates via a seeding
mechanism [58]. In additional experiments, we monitored
the formation of amyloid-like fibrils by A30P or G51D in
solutions without SUVs using a thioflavin T fluorescence
assay. Each aSyn variant was found to undergo fibrillization
at similar rates in the absence or presence of WT ENSA
(Fig. 2a, b), consistent with the idea that ENSA interacts
specifically with membrane-bound aSyn [57]. Importantly,
the incubation of ENSA alone did not result in the forma-
tion of amyloid-like fibrils (Fig. 2c).
Collectively, these results suggest that (i) WT ENSA inter-
feres with membrane-induced aSyn aggregation; (ii) the in-
hibitory effect of ENSA on aSyn self-assembly in the presence
of SUVs depends strictly on the ability of ENSA to bind aSyn
at themembrane surface; and (iii) ENSA has no effect on aSyn
fibrillization in the absence of SUVs.
Effect of ENSA on aSyn-mediated membrane disruption
Data from several studies suggest that aSyn self-assembly at
the membrane surface can promote a disruption of bilayer in-
tegrity via a mechanism involving phospholipid extraction by
the growing aggregates [37, 44]. Accordingly, we hypothesized
that (i) membrane-induced aSyn aggregation should result in
vesicle disruption, and (ii) vesicle disruption resulting from
membrane-induced aSyn self-assembly should be attenuated
by ENSA. To address this hypothesis, we developed a mem-
brane permeabilization assay in which 50 nm PG:PC SUVs
pre-loaded with the fluorescent dye calcein at a concentration
that resulted in self-quenching were incubated with mono-
meric aSyn. Vesicle disruption was assessed by monitoring
the increase in fluorescence emission resulting from
dequenching of the fluorophore upon its release from vesicles
and dilution in the surrounding medium. Extended incuba-
tion of calcein-loaded SUVs (800 μM) with monomeric A30P
or G51D (40 μM) at 37 °C produced a time-dependent
increase in fluorescence emission, with a yield of al-
most 75% of the maximal signal (obtained by lysing
the vesicles with the detergent Triton X-100) after
120 h (Fig. 3a-d). Because the non-toxic aSyn variant
A29E, previously shown by our group to have a low
Fig. 1 WT ENSA (but not the S109E mutant) inhibits membrane-induced aggregation of A30P and G51D. A mixture of A30P (a−d) or G51D (e−h)
(40 μM of each) and SUVs was incubated in the absence (−) or presence of WT ENSA (10–40 μM) (a, b, e, f) or in the absence (−) or presence of
WT ENSA or S109E (40 μM) (c, d, g, h) for 72 h. Membrane fractions were isolated and analyzed via Western blotting. (a, c, e, g) Representative
Western blot images (‘olig’ refers to the region of the blot corresponding to high molecular weight forms of aSyn). (b, d, f, h) Bar graphs
showing the ratio of total oligomer intensity to monomer intensity determined via densitometric analysis. The data are presented as the
mean ± SEM, n = 4; *p < 0.05, **p < 0.01, ***p < 0.001 versus control (−); #p < 0.05 versus ‘ENSA, 10 μM’ , one-way ANOVA followed by
Tukey’s multiple comparisons post hoc test
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propensity to undergo membrane-induced aggregation
[58], exhibited little measurable activity in this assay
(Additional file 1: Figure S2), we inferred that A30P
and G51D triggered vesicle disruption via a mechanism
related to their aggregation on the membrane surface.
Co-incubation of A30P or G51D withWT ENSA (10, 20, or
40 μM) resulted in a dose-dependent decrease in calcein release
(Fig. 3a, b; Additional file 1: Table S1). In contrast, the S109E
ENSAvariant did not preventA30P- orG51D-mediated vesicle
permeabilization (Fig. 3c, d; Additional file 1: Table S2). Import-
antly, incubation of ENSAalonewith lipid vesicles had no effect
on dye release (Additional file 1: Figure S3). Collectively, these
data suggested that (i)WTENSA interferes with the disruption
of vesicle integrity resulting from aSyn aggregation at themem-
brane surface, and (ii) this inhibitory effect depends on the abil-
ity of ENSA to bindmembrane-associated aSyn.
Effect of ENSA on aSyn neurotoxicity
Next, we examined whether the ability of ENSA to interfere
with membrane-induced aSyn aggregation and aSyn-
mediated membrane permeabilization translated into an in-
hibitory effect of ENSA on aSyn neurotoxicity. To address this
question, we characterized ENSA in terms of its ability to alle-
viate dopaminergic cell death and neurite retraction elicited
by mutant aSyn in a primary mesencephalic cell culture
model. Cultures were transduced with adenovirus encoding
A30P or G51D in the absence or presence of virus encoding
WTENSA, the S109E ENSAvariant, or the control protein β-
gal. The cells were fixed and stained for microtubule
associated protein 2 (MAP2), a general neuronal marker, and
tyrosine hydroxylase (TH), a marker of dopaminergic neu-
rons. Relative dopaminergic cell viability was assessed by de-
termining the percentage of MAP2+ neurons that were also
TH+ (previous results indicated that the adenoviral transduc-
tion efficiency was >90% for both neuronal populations, and
that the expression of aSyn variants does not result in toxicity
to MAP2+/TH− neurons in this model [58]). We found that
cultures expressing A30P or G51D displayed a significant loss
of TH+ neurons relative to untransduced cultures or cultures
treated with LacZ virus (Fig. 4a, b). Further analysis of the
same cultures revealed that surviving TH+ neurons in A30P-
or G51D-expressing cultures exhibited a significant reduction
in neurite lengths compared to TH+ neurons in untransduced
or β-gal-expressing cultures (Fig. 4c−e). Cultures co-
expressing A30P or G51D plus WT ENSA exhibited mark-
edly greater TH+ cell viability (Fig. 4a, b) and neurite lengths
(Fig. 4c-e) compared to cultures expressing A30P or G51D
alone or co-expressingmutant aSyn and β-gal. In contrast, ex-
pression of the S109E ENSAvariant at a level similar to that of
WT ENSA (Additional file 1: Figure S4) failed to rescue dopa-
minergic cell loss and neurite retraction in A30P- or G51D-
expressing cultures (Fig. 4a−e). No changes in neurite
lengths were observed in midbrain cultures expressing
WT ENSA or S109E in the absence of aSyn
(Additional file 1: Figure S5). Together, these results
indicated that WT ENSA (but not the S109E variant)
alleviated aSyn dopaminergic neurotoxicity in a
primary cell culture model of PD.
Fig. 2 ENSA does not interfere with aSyn fibrillization. The formation of amyloid-like fibrils was monitored in a solution of A30P (a) or G51D (b)
(40 μM of each) with or without ENSA (10–40 μM), or in a solution of ENSA alone (10–40 μM) (c). The protein solutions were incubated at 37 °C
with constant agitation and analyzed at various times for thioflavin T fluorescence. The graphs show the mean fluorescence normalized to the
maximal signal at the end of the incubation (a, b) or the mean, unnormalized fluorescence (c) plotted against the incubation time. The dotted
lines above and below each solid line in (a) and (b) correspond to the mean signal ± SEM; n = 3 (a), n = 4 (b), or n = 2 (c)
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ENSA levels in the brains of human synucleinopathy patients
ENSA was previously shown to be down-regulated in the
brains of patients with AD or Down syndrome [30, 31].
Accordingly, we hypothesized that ENSA levels might be
reduced in the brains of individuals with synucleinopathy
diseases, leading to a decrease in ENSA-mediated neuro-
protection that could contribute to aSyn neuropathology
in these disorders. To address this hypothesis, homoge-
nates were prepared from the frontal cortex and cingulate
gyrus regions of patients with a confirmed neuropatho-
logical diagnosis of DLB and individuals with no obvious
neuropathology, and ENSA levels were determined via
Western blot analysis. We chose to analyze samples from
the frontal cortex and cingulate gyrus because both of
these brain regions show evidence of aSyn neuropathology
in the brains of DLB patients [21, 55]. The brain samples
were prepared from two cohorts, referred to here as the
‘French’ and ‘MGH’ cohorts (Table 1). ENSA was detected
in each sample as a single band corresponding to a protein
with a molecular weight of ~15 kDa (Fig. 5a, c; Fig. 6a, c).
ENSA band intensities determined via densitometric
analysis were normalized to the respective intensities
obtained for the neuronal marker β-3-tubulin to account
for potential neuronal cell loss in the patient samples. The
results revealed a reduction in the mean ENSA level in
cortical samples of DLB patients, relative to age-matched
controls, of ~70% in the French cohort (Fig. 5b; p < 0.01).
Similarly, a strong trend towards such a reduction, result-
ing in a decrease in the mean ENSA level of ~40%, was
observed in the MGH cohort (Fig. 5d). Analysis of
homogenates prepared from the cingulate gyrus of DLB
patients revealed a reduction in the mean ENSA level
of ~60% relative to controls in the French cohort
(Fig. 6a, b; p < 0.01), but no difference in the mean
ENSA level between patients and controls in the MGH
cohort (Fig. 6c, d). In an additional experiment, we
observed a reduction in the mean ENSA level of
~50% in the substantia nigra region of PD patients
versus non-diseased individuals, although this trend
did not reach significance (Additional file 1: Figure
S6a, b; Additional file 1: Table S3). Collectively, these
results suggest that ENSA down-regulation could play
a role in aSyn neuropathology in the brains of synu-
cleinopathy patients.
Discussion
WT ENSA (but not the S109E variant) interferes with
membrane-induced aSyn aggregation
Previous findings reported by our group and others re-
vealed that aSyn undergoes accelerated aggregation in
Fig. 3 WT ENSA (but not the S109E mutant) interferes with vesicle disruption by A30P and G51D. Calcein-loaded SUVs were incubated in the absence
(Control) or presence of A30P (a, c) or G51D (b, d) (40 μM of each), with or without WT ENSA (10–40 μM) (a, b), or with or without WT ENSA or S109E
(40 μM) (c, d). Calcein release was monitored via fluorescence measurements at an excitation wavelength of 485 nm and an emission wavelength of
515 nm. The data are presented as % dye release versus time, with 100% release determined as the signal obtained from vesicles treated with Triton
X-100. Mean ± SEM, n = 3 or 4. P values obtained from a statistical analysis of the data are listed in Additional file1: Tables S1 and S2
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the presence of phospholipid membranes [20, 37], appar-
ently by adopting an exposed, lipid-bound α-helical
structure that favors the formation of β-sheet-rich as-
semblies on the membrane surface [4, 6, 11, 58]. Here,
we confirmed our earlier results by showing that high
molecular-weight, SDS-resistant forms of A30P or G51D
were present in the membrane fraction of aSyn/SUV
mixtures recovered by lipid flotation. These data provide
direct evidence that membrane-bound aSyn oligomers
were formed upon incubation of the protein with SUVs.
The formation of membrane-associated aSyn oligomers
could occur via two mechanisms: (i) the protein could
undergo self-assembly at the membrane surface; or (ii)
the protein could form oligomers in solution and subse-
quently bind to the membrane. Two observations are in-
consistent with the second of these mechanisms. First,
aSyn does not form oligomers in the absence of lipids
under the incubation conditions described here (Griggs
et al., unpublished observations). Second, we find that
the rate at which a given aSyn variant forms oligomers
in the presence of SUVs correlates poorly with the
variant’s intrinsic propensity to undergo aggregation in
the absence of lipids [58].
We hypothesized that ENSA, a protein that interacts
selectively with membrane-bound aSyn [57], would in-
hibit lipid-induced aSyn self-assembly by binding to
aSyn at the membrane surface, thereby disrupting con-
tacts among exposed aSyn conformers leading to aggre-
gate formation. Consistent with this hypothesis, we
observed a marked reduction in levels of aSyn aggregates
in A30P- or G51D-lipid mixtures incubated in the pres-
ence of WT ENSA. Similar amounts of membrane-
associated aSyn were detected in A30P- or G51D-SUV
mixtures incubated with or without ENSA under condi-
tions suitable for aSyn binding but not aggregation, sug-
gesting that ENSA had no major impact on the affinity of
aSyn for phospholipids. Our observation that a sub-
stoichiometric amount of ENSA (relative to aSyn) was
sufficient to alleviate aggregation presumably reflects the
fact that only a fraction of the total aSyn protein was
bound to the membrane at the lipid:aSyn ratio used in
these experiments [58]. Importantly, we found that intro-
duction of the S109E mutation, which mimics PKA phos-
phorylation of ENSA at the highly conserved S109 residue
[24] and prevents the interaction of ENSA with micelle-
bound aSyn [7], completely abrogated the inhibitory effect
Fig. 4 WT ENSA (but not the S109E mutant) alleviates aSyn neurotoxicity. Primary midbrain cultures were transduced with adenovirus encoding A30P
(a, c, e) or G51D (b, d) at an MOI of 10, in the absence or presence of adenovirus encoding WT ENSA, S109E, or the control protein β-gal (LacZ) at an
MOI of 5. Additional cultures were untransduced (‘control’) or transduced with LacZ adenovirus alone. The cells were fixed, stained with antibodies
specific for MAP2 and TH, and scored for dopaminergic cell viability (a, b) or neurite lengths (c, d). The data are presented as the mean ± SEM, n = 3.
(a, b) **p < 0.01, ***p < 0.001, ****p < 0.0001 versus control or LacZ, ##p < 0.01, ###p < 0.001 versus WT ENSA; square root transformation, one-way
ANOVA followed by Tukey’s multiple comparisons post hoc test. (c, d) ****p < 0.0001, Tukey’s multiple comparisons post hoc test after general
linear model implementation. (e) Representative fluorescence images showing the more pronounced retraction of neurites extending from
MAP2+/TH+ neurons in cultures expressing A30P alone or A30P with ENSA S109E compared with untransduced cultures, cultures expressing
β-gal, or cultures expressing A30P with WT ENSA (scale bar, 50 μm)
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of ENSA on membrane-induced aSyn aggregation. This
result strongly suggests that WT ENSA interferes with
aSyn self-assembly at the membrane surface via a direct
interaction with lipid-bound aSyn.
Another key result of our study was the observation
that ENSA has no impact on the ability of aSyn to form
amyloid-like fibrils in the absence of vesicles. This find-
ing is consistent with previous data showing that ENSA
and aSyn only bind to each other at the membrane sur-
face, apparently because both are natively unfolded in
the absence of phospholipids but adopt an α-helical
structure compatible with their interaction upon mem-
brane binding [57]. The fact that ENSA has no impact
on aSyn fibrillization in the absence of lipids suggests
that the inhibitory effect of ENSA on aSyn aggregation
in the presence of SUVs must be related to its inter-
action with aSyn at the membrane surface. This evidence
further supports the idea that aSyn actively oligomerizes
on the membrane when incubated in the presence of
SUVs under the conditions described in this study.
Collectively, our data show for the first time that a
protein can inhibit membrane-induced aSyn aggregation
via an apparent chaperone-like activity at the membrane
surface. NMR chemical shift data revealed that the bind-
ing of ENSA to aSyn in the presence of SDS micelles
primarily involves ENSA residues 28–36 and 88–97,
with a smaller contribution from residues near S109 [7],
and aSyn residues 19–30 and 58–74 [57]. Because
residues 58–74 of aSyn are located in the dissociated,
aggregation-prone region of exposed, lipid-bound con-
formers [6, 58], we infer that ENSA could inhibit
membrane-induced aSyn self-assembly by: (i) disrupt-
ing interactions involving the dissociated region of
neighboring exposed conformers, and/or (ii) promot-
ing binding of the dissociated region to the bilayer,
thereby stabilizing a more hidden form of membrane-
bound aSyn.
WT ENSA (but not the S109E variant) interferes with
aSyn-mediated vesicle disruption
An important outcome of our study was the finding
that aSyn variants trigger vesicle permeabilization
under conditions that promote membrane-induced ag-
gregation. To monitor vesicle disruption, we developed
a novel fluorescence-based assay that reported on the
time-dependent loss of membrane integrity of calcein-
loaded SUVs incubated with aSyn variants initially
added in monomeric form [3, 58]. This assay involves
the extended incubation of aSyn-SUV mixtures under
conditions shown to promote aggregation at the mem-
brane surface (Fig. 1) and is thus distinct from previ-
ously reported dye leakage assays designed to monitor
the permeabilization of phospholipid vesicles immedi-
ately upon the addition of aSyn oligomers prepared in
the absence of membranes [52, 54]. Using this assay,
which served as a direct measure of the physiological
effect of aSyn aggregation at the membrane surface, we
showed that A30P and G51D both triggered membrane
leakage to an extent consistent with the degree of ag-
gregation at each time point [58]. In contrast, the non-
familial mutant A29E, which has a weak propensity to
undergo membrane-induced aggregation [58], failed to
elicit vesicle disruption, strongly suggesting that aSyn-
mediated membrane permeabilization is closely related
(or even coupled) to aSyn self-assembly at the membrane
surface. Oligomeric aSyn prepared in the absence of
membranes was previously shown to permeabilize low-
diameter vesicles composed of anionic lipids, but not a
mixture of anionic and zwitterionic lipids [54]. Consistent
with these findings, pre-formed aSyn oligomers were in-
active in our assay using PG:PC SUVs. Together, these ob-
servations suggest that the vesicle permeabilization
observed in aSyn-SUV mixtures in this study occurs as a
result of aSyn aggregation at the membrane surface,
possibly via a mechanism involving lipid extraction
from the bilayer and membrane thinning [11, 37, 44].
This evidence further supports the idea that aSyn forms
Table 1 Summary of demographic information for donors of
cortical and cingulate gyrus samplesa
Case Age (y) Sex Braak stage PMI (h) Neuropathological
diagnosis
GIE Neuro-CEB BB-0033-00011 (France)
CTRL-1 79 M n/a nd control
CTRL-2 73 M n/a 10 control
CTRL-3 78 M n/a 23 control
CTRL-4 60 F n/a 28 control
DLB-1 74 M nd 21 DLB
DLB-2 83 F nd 12 DLB
DLB-3 81 M 6 nd DLB
DLB-4 85 M 3 21 DLB
Massachusetts General Hospital (MGH)
CTRL-1 94 M n/a 17 control
CTRL-2 54 M n/a 6 control
CTRL-3 58 F n/a 18 control
CTRL-4 92 M n/a nd control
DLB-1 62 M 5 <24 DLB
DLB-2 61 M 6 20 DLB
DLB-3 65 F 6 10 DLB
DLB-4 80 F 6 nd DLB
Abbreviations: PMI post-mortem interval, M male, F female, n/a not applicable,
nd not determined
aBrain samples used for ENSA expression analysis were obtained from DLB
patients and neuropathologically normal (control) individuals from two
cohorts. The average age was 72.5 y (France) and 74.5 y (MGH) for control
individuals, and 80.8 y (France) and 67.0 y (MGH) for DLB patients
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aggregates on the membrane surface under the experi-
mental conditions described here.
Importantly, we found that WT ENSA interfered with
membrane disruption triggered by A30P or G51D. This
inhibitory effect was highly dose-dependent, with a
significant reduction in permeabilization observed at an
ENSA:aSyn ratio as low as 1:4 (mol/mol) – again imply-
ing that only a fraction of the total aSyn protein was
bound to the membrane under these experimental con-
ditions. In contrast to WT ENSA, the S109E variant
Fig. 6 ENSA expression levels are reduced in the cingulate gyrus region of a subset of DLB patients. Tissue samples consisted of the cingulate
gyrus region of DLB patients and aged-matched controls from two cohorts, provided by GIE Neuro-CEB (a, b) and Massachusetts General Hospital
(c, d). The tissues were homogenized and examined for ENSA expression via Western blotting. (a, c) Images of Western blots probed with a primary
antibody specific for human ENSA (upper panel), β-3-tubulin (middle panel), or β-actin (lower panel). (b, d) Bar graphs showing relative ENSA
expression levels determined via densitometric analysis of Western blots for the individual cohorts. ENSA band intensities were normalized to the
corresponding β-3-tubulin signals and divided by the mean value obtained for the control samples. The data are presented as the mean ± SEM,
n = 4, **p < 0.01, two-tailed Student’s t-test
Fig. 5 ENSA expression levels are reduced in the cortex of DLB patients. Tissue samples consisted of the frontal cortex region of DLB patients and
aged-matched controls from two cohorts, provided by GIE Neuro-CEB (a, b) and Massachusetts General Hospital (c, d). The tissues were homogenized
and examined for ENSA expression via Western blotting. (a, c) Images of Western blots probed with a primary antibody specific for human ENSA (upper
panel), β-3-tubulin (middle panel), or β-actin (lower panel). (b, d) Bar graphs showing relative ENSA expression levels determined via densitometric
analysis of Western blots for the individual cohorts. ENSA band intensities were normalized to the corresponding β-3-tubulin signals and
divided by the mean value obtained for the control samples. The data are presented as the mean ± SEM, n = 4, **p < 0.01, two-tailed Student’s t-test
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had no effect on A30P- or G51D-induced membrane
permeabilization, suggesting that WT ENSA attenuated
aSyn-mediated vesicle disruption by binding directly to
membrane-associated aSyn. Our observation that WT
ENSA (but not S109E) inhibited both membrane-induced
aSyn aggregation and vesicle disruption underscores the
idea that these phenomena are closely related. Accord-
ingly, ENSA-aSyn interactions responsible for disrupting
aSyn self-assembly at the membrane surface could also
be involved in suppressing membrane permeabilization.
To our knowledge, this is the first report of a protein
with the ability to inhibit aSyn-mediated vesicle dis-
ruption via an apparent chaperone-like activity at the
membrane surface.
WT ENSA (but not the S109E variant) interferes with aSyn
neurotoxicity
In a previous report, we showed that A30P and G51D
had a greater propensity than WT aSyn to undergo
lipid-induced self-assembly at the membrane surface and
elicit dopaminergic cell death in primary midbrain cul-
tures [58]. Here, we showed that the neurotoxicity of
both aSyn variants was alleviated by co-expressing WT
ENSA, but not the S109E variant. Based on the evidence
reported here that WT ENSA, but not S109E, interferes
with membrane-induced aSyn aggregation and aSyn-
mediated vesicle disruption via a chaperone-like activity,
we infer that the ability of ENSA to inhibit these patho-
logical effects of aSyn at the membrane surface plays a
central role in its neuroprotective activity.
Although A30P and G51D are rare familial aSyn mu-
tants, the effects of ENSA on the aggregation propensity,
permeabilization activity, and neurotoxicity of these vari-
ants as reported here are likely relevant to sporadic PD
and other synucleinopathy disorders including DLB
because there is evidence that the neuropathological fea-
tures elicited by WTaSyn in the brains of synucleinopathy
patients overlap with those caused by aSyn substitution
mutants in familial PD [29, 46]. In addition, PD patients
with a duplication or triplication of the aSyn gene
have similar clinical and neuropathological phenotypes
compared to patients with familial aSyn substitutions,
suggesting that the neurotoxicity of WT aSyn is re-
lated to, but intrinsically more moderate than, that of
the familial substitution mutants. Consistent with this
idea, membrane-bound WT aSyn has been shown to
adopt a more exposed, aggregation-prone conformation at
higher protein-to-lipid ratios [6]. Moroever, by ana-
logy with the effects of aSyn mutations, membrane
perturbations including lipid oxidation and changes in
lipid composition observed in synucleinopathy patients
[15, 47] would be predicted to favor the self-assembly of
membrane-bound WT aSyn [58]. Under these conditions,
WT aSyn could potentially elicit similar neuropathological
effects as A30P or G51D. Based on this reasoning and
evidence that ENSA interacts with WT aSyn [7, 57], we
predict that ENSA should alleviate aSyn-mediated neu-
rodegeneration in the brains of patients not only with
familial PD, but also with sporadic PD and other synu-
cleinopathy disorders. However, this idea was not tested
here because of the limited neurotoxicity of WT aSyn
in our primary cell culture model [58].
A decrease in ENSA levels is observed in the brains of
synucleinopathy patients
ENSA is a member of a highly conserved family of cAMP-
regulated phosphoproteins that includes ARPP16/19, a
protein that was also found to interact with membrane-
bound aSyn [57]. Members of this family have been most
extensively characterized in terms of their roles in cell
division related to cancer biology [18]. However, these
proteins are also highly expressed in rat brain tissue, par-
ticularly in neurons of the frontal cortex and the basal
ganglia [17, 18]. ENSA has been found to be down-
regulated in the brains of AD patients and individuals with
Down syndrome [30, 31]. Here, we observed a decrease in
ENSA levels in DLB cortex (or a strong trend towards
such a decrease) in two independent cohorts. ENSA levels
were also reduced in the cingulate gyrus of DLB patients
in one of two cohorts examined. The fact that the cingu-
late gyrus samples of DLB patients from the French
cohort, but not the MGH cohort, showed evidence of
ENSA down-regulation may reflect differences in disease
progression between the two sets of patients. Finally, we
observed a pronounced trend towards a decrease in ENSA
levels in the substantia nigra of PD patients.
The fact that patients with the A30P or G51D muta-
tion are characterized by aSyn neuropathology similar to
that in the brains of DLB patients [29, 38, 46] implies
that the two mutants and WT aSyn elicit neurodegener-
ation via similar mechanisms. In turn, we infer that the
inhibitory effects of ENSA on the aggregation propen-
sity, permeabilization activity, and neurotoxicity of A30P
or G51D may be relevant to the effects of ENSA down-
regulation on WT aSyn neuropathology in the brains of
DLB patients. Collectively, our results suggest that (i)
ENSA down-regulation could favor aSyn aggregation
and neurotoxicity in synucleinopathy diseases; and (ii)
up-regulation of ENSA expression in the brains of synu-
cleinopathy patients, at least to basal levels, could be a
viable neuroprotective strategy.
Stabilization of membrane-bound amyloidogenic protein
is a neuroprotective strategy to treat synucleinopathies
and other protein misfolding diseases
Our observation that WT ENSA blocked aSyn self-
assembly at the membrane surface and alleviated aSyn-
mediated dopaminergic cell death, but had no effect on
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aSyn fibrillization in the absence of vesicles, further
highlights the critical role of membrane-induced aSyn
aggregation in aSyn neurotoxicity. The idea that lipid-
induced aSyn self-assembly plays a key role in PD
pathogenesis is also supported by evidence that non-
membrane-bound aSyn exists in a compact, aggregation-
resistant state in mammalian cells, with the central
hydrophobic domain shielded from interactions with
cytosolic components [51]. In turn, this finding im-
plies that membrane binding could serve as a key
trigger for aSyn aggregation by inducing exposure of
the hydrophobic domain.
Collectively, these observations suggest that selectively
targeting membrane-bound aSyn could be a viable
therapeutic strategy for PD and other synucleinopathy
disorders. Previous results obtained by our group and
others revealed that up-regulating molecular chaper-
ones that interact with aSyn in the absence of lipid
membranes, including Hsp27, Hsp70, and DJ-1, could
result in attenuation of aSyn neurotoxicity [32, 39, 40].
Here we propose a different neuroprotective strategy
involving the up-regulation of proteins that bind specif-
ically to membrane-associated aSyn, thereby stabilizing
a more hidden aSyn structure and/or interfering with
interactions among exposed conformers at the mem-
brane surface. In addition to ENSA, other proteins that
have been shown to bind specifically to membrane-
associated aSyn, including PLD2 [26], synaptobrevin-2
[8], and Rab3a [10], could potentially be candidates for
such a membrane-targeted chaperone strategy.
A number of other amyloidogenic polypeptides have
been found to undergo lipid-induced aggregation coupled
to membrane permeabilization, including islet amyloid
polypeptide (IAPP) involved in diabetes [2, 19, 33] and Aβ
peptide associated with AD neuropathology [14]. The re-
sults presented here imply that protein binding partners
could also interfere with the aggregation of these polypep-
tides at the membrane surface. In support of this idea, in-
sulin has been shown to interfere with lipid-induced IAPP
self-assembly, although this inhibitory effect is distinct
from that of ENSA on membrane-induced aSyn aggrega-
tion because it involves the binding of insulin to IAPP fi-
bril ends rather than the membrane and is markedly
greater in the absence than in the presence of lipids [34].
In other studies, peptidomimetics and small molecules
that interfered with membrane-induced IAPP aggregation
were reported to attenuate IAPP cytotoxicity [23, 35].
These observations and the findings presented herein
strongly suggest that stabilizing aggregation-resistant
forms of membrane-bound amyloidogenic polypeptides
by promoting interactions with their binding partners
could be a viable therapeutic strategy not only for synu-
cleinopathy disorders, but also for a broader array of pro-
tein misfolding diseases.
Conclusions
In this study, we observed that the interaction of ENSA
with aSyn at the surface of phospholipid vesicles led to a
decrease in membrane-induced aSyn aggregation and
aSyn-mediated vesicle permeabilization. In addition,
ENSA over-expression led to a decrease in aSyn neuro-
toxicity in primary midbrain cultures, and ENSA was
found to be down-regulated in the brains of synucleino-
pathy patients. These findings suggest that interfering
with aSyn self-assembly at membrane surfaces could
slow neurodegeneration in PD and other synucleinopa-
thies, and they provide a strong rationale for examining
neuroprotective effects of ENSA in animal models of
these disorders.
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